- Home
- WK vs MRUS Comparison
WK vs MRUS Comparison
Compare WK & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WK
- MRUS
- Stock Information
- Founded
- WK 2008
- MRUS 2003
- Country
- WK United States
- MRUS Netherlands
- Employees
- WK N/A
- MRUS N/A
- Industry
- WK Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- WK Technology
- MRUS Health Care
- Exchange
- WK Nasdaq
- MRUS Nasdaq
- Market Cap
- WK 4.3B
- MRUS 3.6B
- IPO Year
- WK 2014
- MRUS 2016
- Fundamental
- Price
- WK $94.37
- MRUS $45.05
- Analyst Decision
- WK Buy
- MRUS Strong Buy
- Analyst Count
- WK 5
- MRUS 10
- Target Price
- WK $103.20
- MRUS $86.70
- AVG Volume (30 Days)
- WK 418.0K
- MRUS 400.6K
- Earning Date
- WK 11-06-2024
- MRUS 10-31-2024
- Dividend Yield
- WK N/A
- MRUS N/A
- EPS Growth
- WK N/A
- MRUS N/A
- EPS
- WK N/A
- MRUS N/A
- Revenue
- WK $705,444,000.00
- MRUS $35,932,000.00
- Revenue This Year
- WK $19.91
- MRUS N/A
- Revenue Next Year
- WK $16.07
- MRUS $52.49
- P/E Ratio
- WK N/A
- MRUS N/A
- Revenue Growth
- WK 16.18
- MRUS N/A
- 52 Week Low
- WK $65.47
- MRUS $22.26
- 52 Week High
- WK $105.00
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- WK 67.15
- MRUS 33.36
- Support Level
- WK $89.39
- MRUS $42.30
- Resistance Level
- WK $95.58
- MRUS $53.49
- Average True Range (ATR)
- WK 2.84
- MRUS 2.29
- MACD
- WK 0.15
- MRUS -1.02
- Stochastic Oscillator
- WK 84.83
- MRUS 17.69
About WK Workiva Inc.
Workiva Inc is a cloud-native platform that simplifies the complexities of reporting and compliance. Workiva platform empowers customers by connecting and transforming data from hundreds of enterprise resource planning (ERP), human capital management (HCM), and customer relationship management (CRM) systems, as well as other third-party cloud and on-premise applications. Customers use the platform to create, review and publish data-linked documents and reports with greater control, consistency, accuracy, and productivity and it is also used for SEC Filings. It provides to more than 6,000 organizations across the globe with SaaS platform solutions to help solve some of the most complex reporting and disclosure challenges.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.